| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The mechanisms behind the therapeutic activity of BET bromodomain inhibition.
|
Mol Cell
|
2014
|
2.47
|
|
2
|
The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.
|
Genes Dev
|
2015
|
2.28
|
|
3
|
Chemical biology. A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes.
|
Science
|
2014
|
1.70
|
|
4
|
Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit.
|
J Med Chem
|
2012
|
1.55
|
|
5
|
Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.
|
Chem Biol
|
2015
|
1.46
|
|
6
|
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells.
|
Elife
|
2015
|
1.46
|
|
7
|
NSD3-NUT fusion oncoprotein in NUT midline carcinoma: implications for a novel oncogenic mechanism.
|
Cancer Discov
|
2014
|
1.27
|
|
8
|
Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia.
|
Leukemia
|
2013
|
1.22
|
|
9
|
Cancer epigenetics drug discovery and development: the challenge of hitting the mark.
|
J Clin Invest
|
2014
|
1.20
|
|
10
|
MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma.
|
Oncogene
|
2013
|
1.16
|
|
11
|
Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching.
|
Epigenetics Chromatin
|
2014
|
1.14
|
|
12
|
Hijacked in cancer: the KMT2 (MLL) family of methyltransferases.
|
Nat Rev Cancer
|
2015
|
1.12
|
|
13
|
RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
|
PLoS One
|
2013
|
1.11
|
|
14
|
The importance of diagnosing NUT midline carcinoma.
|
Head Neck Pathol
|
2013
|
1.10
|
|
15
|
Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.
|
Ther Adv Hematol
|
2015
|
1.06
|
|
16
|
Molecular Pathways: Targeting MYC-induced metabolic reprogramming and oncogenic stress in cancer.
|
Clin Cancer Res
|
2013
|
1.04
|
|
17
|
BET bromodomain proteins are required for glioblastoma cell proliferation.
|
Epigenetics
|
2014
|
0.99
|
|
18
|
Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs.
|
Cancer Cell
|
2016
|
0.98
|
|
19
|
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
|
Cancer Discov
|
2016
|
0.97
|
|
20
|
NUT midline carcinoma: an aggressive intrathoracic neoplasm.
|
J Thorac Oncol
|
2013
|
0.97
|
|
21
|
Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation.
|
Nat Commun
|
2014
|
0.96
|
|
22
|
Epigenetic Readers of Lysine Acetylation Regulate Cocaine-Induced Plasticity.
|
J Neurosci
|
2015
|
0.96
|
|
23
|
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
|
Mol Cancer
|
2015
|
0.94
|
|
24
|
Small cell lung cancer: will recent progress lead to improved outcomes?
|
Clin Cancer Res
|
2015
|
0.94
|
|
25
|
Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.
|
Br J Pharmacol
|
2014
|
0.94
|
|
26
|
Small molecules, big targets: drug discovery faces the protein-protein interaction challenge.
|
Nat Rev Drug Discov
|
2016
|
0.93
|
|
27
|
Bromodomain inhibitors regulate the C9ORF72 locus in ALS.
|
Exp Neurol
|
2015
|
0.91
|
|
28
|
Open access target validation is a more efficient way to accelerate drug discovery.
|
PLoS Biol
|
2015
|
0.90
|
|
29
|
Targeting the histone orthography of cancer: drugs for writers, erasers and readers.
|
Br J Pharmacol
|
2014
|
0.90
|
|
30
|
Genomic and Epigenomic Alterations in Cancer.
|
Am J Pathol
|
2016
|
0.86
|
|
31
|
Clinical trials for BET inhibitors run ahead of the science.
|
Drug Discov Today Technol
|
2016
|
0.86
|
|
32
|
Molecular profiling of childhood cancer: Biomarkers and novel therapies.
|
BBA Clin
|
2014
|
0.86
|
|
33
|
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
|
Prostate Cancer Prostatic Dis
|
2016
|
0.83
|
|
34
|
Digging deep into "dirty" drugs - modulation of the methylation machinery.
|
Drug Metab Rev
|
2015
|
0.83
|
|
35
|
Targeting MYCN: a good BET for improving neuroblastoma therapy?
|
Cancer Discov
|
2013
|
0.83
|
|
36
|
Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
|
Epigenetics
|
2015
|
0.83
|
|
37
|
Drugging Chromatin in Cancer: Recent Advances and Novel Approaches.
|
Mol Cell
|
2015
|
0.81
|
|
38
|
BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.
|
Cancer Med
|
2016
|
0.80
|
|
39
|
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression.
|
Mol Cancer Ther
|
2015
|
0.79
|
|
40
|
Gain-of-function mutation of chromatin regulators as a tumorigenic mechanism and an opportunity for therapeutic intervention.
|
Curr Opin Oncol
|
2015
|
0.79
|
|
41
|
New Synthetic Routes to Triazolo-benzodiazepine Analogues: Expanding the Scope of the Bump-and-Hole Approach for Selective Bromo and Extra-Terminal (BET) Bromodomain Inhibition.
|
J Med Chem
|
2015
|
0.79
|
|
42
|
BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion.
|
Oncotarget
|
2016
|
0.77
|
|
43
|
Chemical synthesis of the ATAD2 bromodomain.
|
Proc Natl Acad Sci U S A
|
2014
|
0.77
|
|
44
|
NUT Carcinoma of the Sublingual Gland.
|
Head Neck Pathol
|
2015
|
0.77
|
|
45
|
Epigenetic Medicinal Chemistry.
|
ACS Med Chem Lett
|
2015
|
0.77
|
|
46
|
Epigenetic modulators as therapeutic targets in prostate cancer.
|
Clin Epigenetics
|
2016
|
0.76
|
|
47
|
Epigenetic Mechanisms Governing Innate Inflammatory Responses.
|
J Interferon Cytokine Res
|
2016
|
0.76
|
|
48
|
Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer.
|
Curr Opin Endocrinol Diabetes Obes
|
2016
|
0.76
|
|
49
|
The molecular mechanics of mixed lineage leukemia.
|
Oncogene
|
2016
|
0.76
|
|
50
|
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
|
Int J Cancer
|
2021
|
0.75
|